GSA Capital Partners LLP Purchases 49,806 Shares of Sarepta Therapeutics, Inc. $SRPT

GSA Capital Partners LLP raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 242.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,371 shares of the biotechnology company’s stock after buying an additional 49,806 shares during the quarter. GSA Capital Partners LLP owned about 0.07% of Sarepta Therapeutics worth $1,514,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in SRPT. iSAM Funds UK Ltd purchased a new stake in Sarepta Therapeutics during the 3rd quarter valued at approximately $25,000. Ancora Advisors LLC grew its holdings in Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,000 shares in the last quarter. Allworth Financial LP grew its holdings in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares in the last quarter. Parallel Advisors LLC grew its holdings in Sarepta Therapeutics by 165.3% during the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,256 shares in the last quarter. Finally, Larson Financial Group LLC grew its holdings in Sarepta Therapeutics by 82.5% during the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 851 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Trading Up 2.9%

SRPT stock opened at $17.12 on Thursday. The firm has a fifty day moving average price of $20.02 and a 200 day moving average price of $20.00. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $44.14. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.62 and a current ratio of 4.63. The firm has a market cap of $1.81 billion, a PE ratio of -17.83, a price-to-earnings-growth ratio of 0.19 and a beta of 0.26.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. The firm had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.16 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. Sarepta Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the firm posted ($3.42) earnings per share. Sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 3.69 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a report on Thursday, March 26th. Royal Bank Of Canada increased their price objective on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a report on Tuesday, April 7th. Mizuho increased their price objective on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, March 12th. Loop Capital set a $25.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a report on Thursday, April 16th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $27.71.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the transaction, the director directly owned 1,765 shares of the company’s stock, valued at $30,040.30. The trade was a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.